Translational Medicine & Biomarker Development: The Lynchpin for the Efficient Drug Discovery and Development Transition.
Jingsong Wang, M.D.,
Director, Discovery Medicine & Clinical Pharmacology
Bristol-Myers Squibb
|
|
Presenter Biography: Dr. Jingsong Wang is a Director, Discovery Medicine & Clinical Pharmacology, at Bristol-Myers Squibb Co (BMS). In his current role, Dr. Wang serves as Exploratory Development Team (EDT) leader oversees a clinical development program with multiple assets targeting several diseases, and directs early to mid-stage clinical studies in Immunology Therapeutic Area.
Dr. Wang joined BMS from Wyeth where he served Associate Director, and later as the group leader for Translational Medicine and Biomarker Development in Inflammation and Rheumatologic Disease Area. Prior to that, Dr. Wang was at Brigham and Women’s Hospital and Harvard Medical School where he was an attending rheumatologist and faculty member. Dr. Wang also completed a research fellowship at the Harvard School of Public Health.
Dr. Wang has published in numerous leading scientific journals and authored a number of textbook chapters related to inflammation and autoimmune diseases. Dr. Wang is board certified in rheumatology, a diplomate of American Board of Internal Medicine.
Dr. Wang’s academic appointments include visiting professorships in China, and he is an Adjunct Assistant Professor of Medicine at University of Pennsylvania, and an attending physician at the Hospital of The University of Pennsylvania. He was on the Research Grant Review Committee on Immunology, National Natural Science Foundation of China (NSFC). Dr. Wang has served as member of the expert panel for Biotechnology Industry Organization (BIO) congressional staff briefing on biotechnology and autoimmune diseases, Capitol Hill, Washington DC.
Online Presentation: http://lifescience.planetconnect.com/ppt/LSPrinceton/tuesday/JINGSONG_WANG.ppt
|
